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ABSTRACT 
Background: Presbyopia is the normal progressive waning of accommodation with loss of the visual ability to focus on 
objects residing at different distances. Presbyopia exacts a cost in quality of life and professional efficiency of many people 
over 40 years of age. Presbyopia is likely to be 1 of the main pressing visual concerns of the 21st century, given that life 
expectancy is increasing, resulting in an aging population. This review aimed to address the 3 strategies of the 
pharmacological treatment for presbyopia. 
Methods: A review on PubMed/MEDLINE, Google Scholar, and Clinicaltrials.gov was performed to investigate the English 
literature on pharmacological treatment for presbyopia from beginning-of-year 2012 to September 30, 2020. 
Results: In addition to the treatment of presbyopia with glasses or contact lenses, new surgical strategies have been 
developed, some of which have been successful. However, during the last decade, a new, promising, non-invasive option 
for treating presbyopia has emerged: the pharmacological approach. Many researchers have developed 3 different lines 
of investigation from different assumptions, on a pharmacological basis. The first consisted of producing miosis, to take 
advantage of a pharmacologically induced pinhole effect, increasing depth-of-focus, and thus improving uncorrected near 
visual acuity. The second aimed to rehabilitate accommodation binocularly to enable good vision at all distances. Finally, 
the third approach attempted to rehabilitate lost elasticity in the human crystalline lens. 
Conclusions: None of the 3 discussed pharmacological strategies for treating presbyopia, prescribed globally, but patients 
of restoring accommodation strategy can adhere locally, where they are sold so far as master prescriptions. 
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INTRODUCTION 
Presbyopia is a refractive condition occurring with aging that 
involves the gradual loss of accommodation, resulting in loss 
of visual performance when focusing on objects residing at 
different distances [1, 2]. Symptoms begin in nearly all people 
at around 40 years of age [3, 4] and are 1 of the first indicators 
of “the passage of time.” People who still feel young, 
experience, for the first time in their life, the need to wear 
spectacles for near tasks, such as reading, stitching, doing 
handcrafts, cooking, and using a computer and cellphone. 
Furthermore, our eyes are stimulated with accommodative 
stimuli in daily activities, intended or not, and this decrease 
in vision exacts a cost in quality of life and professional 
efficiency in many people aged over 40 years [5]. The world 
is facing the Fourth Industrial Revolution, in which innovative 
information and communication technologies, such as 
artificial intelligence, Internet of Things, big data, and 
smartphones are increasingly being used, causing the need 
for the best possible vision and accommodation [6]. 
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21st century, as the population is aging. It has been predicted 
that in 2050, 21% of the global population will be 60 years or 
older [7], and this percentage is likely to increase to nearly 
50% in developed countries [8]. Thus, treatment of 
presbyopia is 1 of the greatest challenges of the 21st century. 
The pathophysiology of presbyopia has not been 
completely elucidated. However, the Helmholtz theory is 
the most widely recognized theory, based on an 
accommodation mechanism. It indicates that the 
crystalline lens thickness increases as its diameter 
decreases, and its anterior and posterior curvature 
increase; therefore, this results in augmentation of the 
crystalline lens power [9]. This is a passive process, 
because the crystalline lens changes are reliant on ciliary 
muscle contraction. In humans, the triad of 
accommodation also requires contraction of the iris 
sphincter, called miosis, and the convergence of both eyes 
[4, 10]. Contraction of the ciliary muscle and iris sphincter 
is mediated by parasympathetic, cholinergic stimulation 
of muscarinic receptors [11], resulting in an increase in the 
depth-of-focus and a change in the crystalline lens shape 
and axial thickness [12]. 
Currently, there are a few different treatments for 
presbyopia, ranging from non-invasive options to a 
succession of surgical techniques. The less-invasive option 
includes reading spectacles, bifocal, trifocal, or progressive 
spectacles. Although spectacles fulfill the goal of correcting 
presbyopia, they are sometimes not very comfortable. For 
instance, the need for different focal distances or learning 
how to direct the visual axes in a specific direction for suitable 
vision can be unpleasant. In addition, some people may not 
like their appearance when wearing spectacles or their 
dependence on spectacles for performing any near activity. 
Another option for optical treatment is contact lens 
correction, which can include contact lenses for distance 
correction, adding near vision spectacles to read, or 
monovision contact lenses, whereby the dominant eye is 
adjusted for distance and the fellow eye for near, and bifocal 
or multifocal contact lenses [13]. This option is more 
convenient for those who do not like to wear spectacles or 
take part in more athletic activities, but for using them all day 
long, good lacrimal production and tear stability are required, 
which is sometimes lacking in presbyopes. Additionally, use 
of contact lenses require proper care and hygiene [10-13]. 
Various surgical procedures have been proposed for 
presbyopia, although not all patients are suitable for all 
possible surgeries, and each technique has its own 
limitations. Through the use of new laser procedures and 
ablation profiles, corneal refractive surgery for presbyopia is 
growing. Presby laser in situ keratomileusis (PresbyLASIK) 
utilizes the principles of LASIK to generate a multifocal 
corneal surface using different profiles, central, peripheral, or 
blended vision. Depending on the profile of choice, far vision 
will be preserved, but near vision will be compromised or the 
other way around [14]. Although the reported spectacle 
independence is good, the main limitation is the corneal 
structure itself, the inconvenience of implanting a multifocal 
intraocular lens (IOL) in future, and different possible 
complications, which sometimes cause irreversible effects 
[15, 16].  
Another approach for correcting presbyopia is 
intracorneal inlay implantation, whereby a lenticule is 
placed at the interface of the cornea. The procedure is 
minimally invasive and reversible. The main complications 
include decentration; biological intolerance, with corneal 
opacity; late hyperopic shift; and poor visual performance 
resulting from corneal irregularity [17]. In addition, some 
cases of explantation have been reported [18]. Another 
reversible treatment option is the implantation of a phakic 
lens in either the anterior or posterior chamber. The main 
complications described with this approach are corneal 
endothelial cell loss, uveitis, glaucoma, pupil deformation, 
and cataract development [19]. 
The emergence of a wide range of IOLs, including monofocal, 
extended depth-of-focus (EDOF), and multifocal with 
multifocal effects, make refractive lens exchange one of the 
most popular treatments for presbyopia [20]. Although 
multifocal IOLs increase spectacle independence and yield 
good visual results for near and distance vision, the main 
complications consist of an unpredictable neuroadaptation 
process, the presence of halos, and glare [17, 21]. With a 
monofocal alternative, using correction for emmetropia in 
the dominant eye and a selected degree of myopia in the 
non-dominant eye, it is possible to have successful visual 
results, with less dysphotopsia symptoms than with 
multifocal IOLs, but at the cost of stereopsis and reduced 
contrast sensitivity [22]. The newest options are EDOF IOLs; 
reports show that these IOLs can deliver suitable vision for 
near and intermediate distances, with fewer halos and glares 
[23]. All these options raise the possibility of common 
complications of intraocular surgery and invasive 
procedures. Thus, performing clear lens surgery in young 
patients with presbyopia, low refractive error, and healthy 
eyes is promising but remains controversial at present [24, 
25]. 
During the last decade, a new promising option for 
treating presbyopia has emerged, in the form of a 
pharmacological approach [26-28]. In contrast to all the 
above-described techniques, this method is not invasive 
and provides good vision at all distances. Many 
researchers have developed different lines of 
investigation based on different assumptions, on a 
 
  
Med Hypothesis Discov Innov Optom. 2020; 1(2)  
69 OVERVIEW OF PHARMACOLOGICAL TREATMENTS FOR PRESBYOPIA 
pharmacological basis. To date, 3 main guidelines have 
been followed. The first consists of inducing miosis to take 
advantage of a pharmacologically induced pinhole effect, 
enhancing the depth-of-focus, and thus improving the 
uncorrected near visual acuity (UNVA) [29-31]. The second 
approach aims to rehabilitate accommodation 
binocularly, allowing good vision at all distances [5, 32]. 
Finally, the third method attempts to rehabilitate the lost 
elasticity of the crystalline lens by decreasing the effect of 
aging [33]. The aim of this review was to summarize the 






We conducted a comprehensive search of 
PubMed/MEDLINE, Google Scholar, and Clinicaltrials.gov 
to identify the English literature on pharmacological 
treatment for presbyopia. We identified relevant articles 
using the keywords “presbyopia”, “presbyopia 
treatment”, “eyedrops”, and “pharmacological 
presbyopia treatment” deposited in these databases from 
beginning-of-year 2012 to September 30, 2020. Finally, 
the authors outlined the results by summarizing 3 lines of 
investigation of pharmacological treatment for 
presbyopia, namely producing miosis to take advantage of 
a pharmacologically induced pinhole effect, restoring 
accommodation, and attempts to rehabilitate the lost 
elasticity of the crystalline lens.  
Table 1: Studies evaluating the efficacy of pharmacological treatment for presbyopia by the pinhole effect. 
Authors/ 
Owners 











Instilled in both eyes  
4 -8 hours 
Miosis 1.5 – 2 mm 
Age: 46‒63 years  
Placebo: no 
N/A 3‒7 lines improvement of 
UCNVA on the Jaeger scale with 
constant distance vision 
Conjunctival injection, stinging 
upon instillation. Although some 
minimal dimming indoors is likely 
for the first few days of use, 
subjects claimed that this effect 
was limited to the first few days of 
treatment. 
Abdelkader 





Instilled in non-dominant 
eye, once daily 
48 emmetropic, 
presbyopic subjects 
Age:  43‒56 years 
3 months 4-line mean improvement of 
UNVA following 1 hour of eye 
drops instillation with 
progressive regression to 1‒2 
lines at 10 hours, with constant 
UDVA 
 Mild burning sensation  



















Instilled in both eyes  
81 Patients: 
10 eyes pseudophakic,  
4 eyes cataracts, 
10 eyes postLASIK/PRK, 
57 presbyopic without lens 
opacity. 
Age: 42–74 years 
Placebo: no 
N/A After treatment with 1‒2 
drops, the mean pupil diameter 
decreased significantly from 
3.77 mm to 2.63 mm. Mean 
depth-of-field increased 
significantly from 1.6 D to 2.6 D. 
Both mean UDVA (from 0.9 to 
1.1) and UNVA (0.3–0.6) 
improved significantly. 
Nausea: quickly resolved 
Headache: 10–15 min 
Dryness or burning 
Stinging 




















Unilateral and bilateral 
65 Participants 
Mean age: 49.2 years  
Placebo: no 
3 days Instillation of AGN-190584 
alone revealed at least 2 lines 
of improvement from baseline 
UNVA in 70.6% of patients, 
while using both agents in both 
eyes resulted in improvements 
in 68.8%, and using AGN-
199201 alone resulted 
improvements in 46.7%  
AGN-199201 (Oxymetazoline): 
Eyelid retraction in 26% of the 
group using oxymetazoline alone.  
AGN-190584: AGN-190584 group 
had 1 case each of blurred vision, 
hyperemia, lacrimation, and eye 
irritation. 
Pilocarpine: None 
Abbreviations: h, Hours; mm: milimiters; N/A, not available; UNVA, uncorrected near visual acuity; UDVA, Uncorrected distance visual acuity; NSAID, non 
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Table 2: Studies evaluating the efficacy and security of pharmacological treatment for presbyopia by restoring accommodation. 
Abbreviations: CNVA, corrected near visual acuity; CDVA, corrected distance visual acuity; UNVA, uncorrected near visual acuity; UDVA, uncorrected distance 
visual acuity; s of arc, seconds of arc; SD, standard deviation; logMAR, logarithm of the minimum angle of resolution; J, Jaeger 
RESULTS  
Pinhole Effect 
Some new pharmaceutical treatments have been 
proposed that are based on the pinhole rationale  to take 
advantage of pharmacologically induced miosis through 
the judicious use of miotics [44]. Small aperture optics 
blocks peripheral light waves, which are most distorted by 
refractive error, and allow only the most central rays of 
light to enter the retina, resulting in clearer vision and an 
increase in the depth-of-field. Moreover, other options for 
presbyopia are founded on a similar effect, such as the 
Kamra corneal inlay [45] and IOLs that contain a central 
aperture [46] and claim to achieve an expanded depth-of-
focus, without significant visual degradation when 
implanted in the non-dominant eye. Pinhole glasses have 
also been studied and proved to reduce the required 
accommodation by 10‒15% [6]. 
The approach proposed by the company Presbyopia 
Therapies is known as liquid vision PRX-100. This is a 
binocularly instilled drop with a combination of aceclidine 
and tropicamide, which has a pure miotic effect with 





























All patients improved CNVA to J1 and it was 
maintained for 5 years. 
CDVA remained at 20/20 and was constant 
during the study period. 
 
1% of the patients discontinued 
treatment due to ocular burning 
and discomfort, and 4% 












All patients improved CNVA to J1 and CDVA 
remained at 20/20 during the year.  
Patients showed an improvement in the 
lachrymal film and the cornea-conjunctival 
surface. The results for eyelid and bulbar 
conjunctival impression cytology showed 




















All the patients maintained an UNVA 
between J1 and 2 during the 8-year period. 
The mean ± SD of UDVA at baseline was 
0.00 ± 0.01 logMAR and after 8 years of 
follow-up was 0.03 ± 0.04 logMAR. 
Dimness, headaches, symptoms 
of ocular surface dryness, and 
dizziness were spontaneously 
resolved in patients who 
continued with the treatment. 
1 hour 20 patients 
Age: 40‒55 
years [42] 
The mean ± SD of UNVA was 0.197 ± 0.02 
LogMAR and 30 min after eye drop 
instillation, CNVA improved to 0.02 ± 0.06 
LogMAR (18 cases with J1 and 2 with J2). 
Pre-treatment mean ± SD of stereopsis was 
200.5 ± 190.85 s of arc, which improved to 
58 ± 22.38 s of arc after pharmacological 
treatment. 
None 




























































CNVA improved by 1 or more lines (mean 
0.18 lines) in 92.3% of the patients, while 
7.7% did not show improvement, at 2 
hours after eye drop instillation. The group 
with the youngest patients achieved more 
lines of improvement than the group with 
the oldest patients. 
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minimal stimulation of accommodation [30]. This 
combination produces a pinhole effect with strong miosis 
and without inducing significant ciliary body spasms, such 
as brought about by pilocarpine, and thus avoids brow 
ache and any myopic shift that would disturb distance 
vision. Aceclidine is less potent than pilocarpine and 
carbachol muscarinic agonists. Opposing this effect, 
tropicamide induces pupil dilatation with minimal 
influence on accommodation because it has a stronger 
affinity for iris M3 receptors than other antimuscarinic 
agents [47]. A 1-day pilot study examining nine presbyopic 
subjects treated with PRX-100 drops revealed that the 
effect on the pupil was achieved 30 min after application, 
reaching a pupil diameter of approximately 1.6 
millimeters (mm, for 5 and 8 h) [34]. According to 
Presbyopia Therapies, Dr. Castillejos in Mexico performed 
a preliminary trial where UNVA improved three to seven 
lines on the Jaeger scale without impairing distance vision 
[30]. Additionally, a clinical trial phase II to verify the 
dosing, safety, and efficacy of PRX-100 in the treatment of 
early to moderate presbyopia in 2017 recruited 58 
patients, but the results have not been released to date 
[35]. 
Abdelkader in 2015 proposed another concept for 
pharmacological control of presbyopia [36]. The principle 
is driven by the rationale of stimulating parasympathetic 
innervation and increasing depth-of-focus via miosis by 
instilling a combination of carbachol 2.25% and 
brimonidine 0.2% eye drops monocularly [36]. On the 1 
hand, brimonidine, an α2-receptor agonist used in 
glaucoma, induces pupillary action, producing significant 
miosis, mainly under low light conditions [48]. 
Brimonidine binds to receptors on the presynaptic nerve 
endings of the dilator muscle and obstructs further release 
of the neurotransmitter into the synaptic cleft, thus 
reducing the activity of the dilator muscle, generating a 
more miotic pupil [37]. In contrast, carbachol, unlike 
pilocarpine, is a full parasympathomimetic agent that 
stimulates the muscarinic and nicotinic receptors on the 
iris sphincter muscle to produce miosis, increase the 
depth-of-focus [34], and promote acetylcholine release 
from parasympathetic nerve endings. To induce miosis, 
the most commonly used strength of carbachol is 2.25%, 
which corresponds to approximately 3% pilocarpine [49, 
50]. 
In 2015, Abdelkader A. published a prospective 
randomized double-masked placebo-controlled clinical 
trial that recruited 48 emmetropic presbyopic patients 
aged 43‒56 years. The study aimed to evaluate the 
efficacy of the use of eye drops containing carbachol 
2.25% and brimonidine 0.2% monocularly once daily for 3 
months [36]. This achieved a mean improvement in UNVA 
of 4 lines on the Jaeger scale at 1 h after instillation of the 
drops, which gradually reverted to 1‒2 lines at 10 hours, 
without deteriorating the uncorrected distance visual 
acuity (UDVA). The described side-effects were reported 
by patients as a mild burning sensation in 3.3%, a dull 
headache in 10%, and difficulty in low luminosity 
(dimness) in 3.3% for the first 2 weeks [36]. 
Another study from the same study group compared 3% 
carbachol with 0.2% brimonidine in 10 patients with 
presbyopia, between 42 and 58 years old, and found 
statistically significant improvement in mean near visual 
acuity following use of combined eye drops as compared 
with use of separate forms [37]. 
In addition, the researchers evaluated the effects of 
various concentrations of pilocarpine and brimonidine, 
pilocarpine alone, and carbachol with and without 
brimonidine, compared with a placebo. To produce a 
pharmacological pinhole effect, in addition to clear vision 
in the eye, they instilled drops for the non-dominant eye. 
The near vision of the fellow eye, with the normal pupil, 
was blurred to some extent, but distant vision was clear, 
and there was no dimmed light perception. They also 
aimed to determine whether brimonidine could prolong 
the effect of cholinergic agonists and achieve an 8-hour 
effect using carbachol and brimonidine once daily [48]. 
This approach was also attempted in pseudophakic 
patients between 30 and 80 years of age. It was found that 
the use of 1 eye drop daily of a combination of carbachol 
and brimonidine could obtain adequate reading vision for 
25 pseudophakic patients [51]. 
Based on these previous studies, in September 2020, Visus 
Therapeutics Inc. announced that Brimochol phase II trials 
would commence in 2021. This formulation combines 
carbachol and brimonidine tartrate [52] .  
The use of parasympathomimetic drops, such as 
pilocarpine and carbachol, and physostigmine, an 
anticholinesterase inhibitor, likely results in chronic 
inflammation due to muscarinic stimulation of the 
anterior uveal tract and causes fixed pupil, posterior 
synechiae, and spasmodic contractions of the iris, pigment 
dispersion, and myopic shift [47]. Furthermore, it has 
been described that non-steroidal anti-inflammatory 
drugs (NSAIDs) inhibit cyclooxygenase (COX) activity and 
act as anti-inflammatory agents in the anterior uveal tract, 
reducing miosis and spasmodic ciliary contractions, 
pigment dispersion, and posterior synechia; thus, NSAIDs 
are combined with miotics [11, 53]. 
PresbiDrops (PresbiDrops, FEPASAET Group, Israel)  
include an oil-based undisclosed combination of a 
parasympathomimetic agent with an NSAID [29].              
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The basis of PresbiDrops is consistent with the eye drops 
studied by Abdelkader. The study presented by Feinbaum 
C. included 81 heterogeneous patients aged 42‒74 years 
(10 eyes were pseudophakic, 4 had cataracts, 10 were 
post-LASIK or PRK, and 57 were presbyopic with a clear 
crystalline lens). The patients received binocularly 
instillation of 1 or 2 eye drops, and the mean pupil 
diameter reduced significantly from 3.77 mm to 2.63 mm. 
The pseudophakic group presented substantial 
improvements in both UNVA and UDVA, while post-
refractive surgery patients maintained 20/20 distance 
UDVA and had a significant improvement in UNVA from 
0.4 to 0.7[29]. The local side effects described were 
dryness or burning (2 patients), stinging (4 patients), and 
blurry distance vision (4 patients). Three-fourths of the 
patients showed no adverse events, 4 patients had nausea 
after instillation (with rapid resolution), and 4 patients had 
a  headache with gradual reversibility within 10–15 min 
[29]. PresbiDrops is undergoing phase II clinical trials to 
evaluate is safety and efficacy in presbyopia treatment. 
This was a 15 days study with 166 participants, although 
the final results are not yet available [38]. 
A Spanish patent of Rodríguez and Carrera combined 
pilocarpine with bromfenac as an NSAID [39]. Bromfenac 
was used to target COX-2 pro-inflammatory mediator 
production. In contrast to both COX-1 and COX-2 
inhibitors, the agents that selectively inhibit COX-2 are 
thought to block inflammation without altering the 
regular homeostatic body mechanisms [54]. Furthermore, 
bromfenac is considered to extend the activity up to 24 
hours, allowing for a once-daily topical application. They 
use this combination monocularly in patients after the 
LASIK procedure [39]; however, to date, no published 
studies are available based on this formulation.  
Allergan Inc. announced phase IIa data from a study 
comparing oxymetazoline (AGN-199201), low-dose 
pilocarpine, or both drugs combined [31, 40]. 
Oxymetazoline, as an α-adrenergic agonist, produces 
mydriasis by acting on the α-receptor of the iris dilator 
muscles, thus diminishing the depth-of-focus. Moreover, 
it is used as an ocular anti-hyperemia agent due to its 
vasoconstrictive effect. However, AGN-199201 may be 
combined with AGN-190584 to reduce its side effects, 
such as hyperemia, or to strengthen its effect by 
weakening systemic absorption and extending 
maintenance time in the eye [30]. 
In a clinical trial with a 3-day study period, 65 participants 
with a mean age of 49.2 years were recruited to 
investigate the safety and efficacy of two types of eye 
drops labeled as AGN-199201 and AGN-190584. UNVA 
was assessed without corrective lenses in the non-
dominant eye. The percentage of patients with at least 2 
or more lines of improvement in UNVA in the non-
dominant eye was 70.6% in the group treated with AGN-
190584 alone, 68.8% when both agents were used 
binocularly and only 46.7% in the group that received 
AGN-199201 alone [55]. Table 1 summarizes studies 
which evaluated the efficacy of pharmacological 
treatment for presbyopia by the pinhole effect. 
Restoring Accommodation 
Accommodation is the physiological, active process that 
allows changing of the optical power of the crystalline lens 
to perceive a clear image of objects when changing focus 
at all distances [9]. 
Accommodation takes place via ciliary muscle contraction 
by modifying the shape and position of the crystalline lens, 
accompanied by the iris sphincter contractions and 
convergence [9]. Presbyopia is the progressive loss of 
accommodation and, consequently, the inability to focus 
on objects situated at different distances. The amplitude 
of accommodation decreases gradually up to 65-year of 
age, when it is almost completely lost. However, the 
amplitude of accommodation allows enough adaptive 
diopters to focus on objects until the sudden onset of a 
deficit in most people, and thus presbyopia appears [56]. 
Accommodation at near depends on ciliary muscle 
contraction, depth-of-focus, and stereopsis. However, 
over time, the possibility of focusing on distant objects 
would also decrease, arriving at the impossibility of 
accommodation at all distances [9]. 
The following 2 methods to treat presbyopia, Benozzi’s 
method [57] and FOV tears [32], are based on binocular 
accommodation restoration through the stimulation of 
parasympathetic receptors, and consequently restoring 
the ability to focus at all distances. This rehabilitation was 
evaluated by measuring UNVA and UDVA. 
Pharmacological treatment of presbyopia began in 2012 
with the publication of the first results of Benozzi’s 
method [11]. Since then, this group has published 3 more 
full papers concerning the different aspects of this 
treatment. The development of this method involves the 
use of eye drops containing a combination of pilocarpine 
at different concentrations and a fixed concentration of 
diclofenac. The treatment is personalized, and its 
prescription is based on the initial condition of the patient 
and their ophthalmology follow-up [5, 11, 41]. 
The first paper on this topic referred to a study of 100 
patients who were followed for 5 years, with an age range 
of 45‒50 years. The treatment consisted of eye drop 
instillation twice in each eye at a 6-hour interval during 
day-time hours. All patients reached Jaeger 1 for near 
vision, and distance vision remained at 20/20 in the first 
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year of treatment. The improved vision was maintained 
for 5 years. Of all the patients, 1% stopped treatment due 
to ocular burning and discomfort, and 4% preferred 
treatment with glasses [11]. 
The second paper is a study of the ocular surface integrity 
and tear production in patients under Benozzi’s 
pharmacological treatment for presbyopia for 1 year. 
Fifteen male patients aged 45–55 years were included. In 
this case, near and distance visual acuity was evaluated in 
addition to the Schirmer test, tear film break-up time, 
corneal staining with fluorescein, and conjunctival 
staining with lissamine green and rose Bengal; and 
conjunctival impression cytology at baseline and 1 year 
later. The UNVA baseline values ranged between Jaeger 2 
and Jaeger 5, and UNVA reached Jaeger 1 at the first 
appointment and remained steady after 1 year of 
pharmacological treatment. The UDVA was 20/20 
following treatment initiation and remained constant 
after 1 year of treatment. The tear film break-up time 
increased significantly, indicating recovery of the tear film, 
whereas the Schirmer test showed no changes during this 
period. The results of fluorescein, lissamine, and rose 
Bengal stains indicated the recovery of the corneal-
conjunctival surface of the patients receiving the 
treatment. The results of eyelid and bulbar conjunctival 
impression cytology showed no changes during this study. 
These results indicate that the pharmacological treatment 
for presbyopia produced a corneal‒conjunctival surface 
recovery, with no changes in tear production and corneal 
epithelium following 1 year of chronic eye drop use [41]. 
The third paper reports on an 8-year prospective study of 
910 patients aged 40–59 years, to evaluate the safety and 
efficacy of topical treatment with Benozzi’s method for 
presbyopia. This study included patients with emmetropia 
with binocular UDVA of 25/20 logMAR or better and with 
UNVA at least Jaeger 2 or worse. The baseline UNVA was 
4.74 ± 1.53 Jaeger scale and at 8 years of follow-up was 
decreased to 1.36 ± 0.48 Jaeger scale. All patients were 
maintained for 8 years with a UNVA between Jaegers 1 
and 2. The mean ± standard deviation (SD) of binocular 
UDVA at baseline was 0.00 ± 0.01 logMAR and after 8 
years of follow-up was 0.03±0.04 logMAR. The side effects 
reported were a decrease in light perception, headaches, 
symptoms of ocular surface dryness, and dizziness, which 
were spontaneously resolved in patients who continued 
with the treatment [5]. 
A topic directly related to accommodation was addressed 
in the fourth study, i.e., stereopsis. A non-randomized 
case-series prospective study investigated 20 emmetropic 
patients aged 40–55 years. Measurements of the spherical 
equivalent (SE) refraction, UDVA, monocular UNVA, 
monocular corrected distance visual acuity (CDVA), 
corrected near visual acuity (CNVA), ocular motility, and 
stereopsis were performed in 3 situations: at baseline, 
with optical correction (wearing eyeglasses), and 30 min 
after treatment (eye-drop instillation). The mean ± SD of 
SE refraction in the right eye was 0.34 ± 0.32 D and in the 
left eye, it was 0.23 ± 0.22D. Orthophoria was found in 
85% of patients while 15% had exophoria. The mean ± SD 
of UNVA was 0.197 ± 0.02 LogMAR; with optical correction 
patients achieved Jaeger 1 (0 LogMAR) and after 
pharmacological treatment, the mean ± SD of CNVA was 
0.02 ± 0.06 LogMAR (18 cases with Jaeger 1 and 2 with 
Jaeger 2). Pre-treatment mean ± SD of stereopsis was 
200.5 ± 190.85 seconds of arc using a Titmus Stereo 
Optical test, which improved to 52.5 ± 19.70 seconds of 
arc (P < 0.0018) after the optical correction and to 58 ± 
22.38 seconds of arc (P < 0.002) after pharmacological 
treatment. Both methods exhibited similar stereoscopic 
results, thus adding more evidence that the treatment re-
established near visual acuity as well as stereopsis [42]. 
A group from South America, developed another 
pharmacological treatment. In this case, the ophthalmic 
formulation combined pilocarpine 0.247%, with the NSAID 
nepafenac 0.023%, with the addition of phenylephrine 
(0.78%), pheniramine (0.034%), naphazoline (0.003%), 
and polyethylene glycol (0.09%). This group has published 
2 papers regarding their pharmacological treatment 
results [32, 43]. 
The first paper, from 2016, by Renna et al., studied the 
safety and potential efficacy of this ophthalmologic 
formulation in 14 patients (9 natural emmetropes, 5 
stable emmetropes post-LASIK), with an age range of 41–
55 years. For each patient, the UDVA, UNVA, near and 
distance refraction, CDVA, CNVA, photopic and scotopic 
pupil size, Schirmer’s test, endothelial cell count, 
intraocular pressure, keratometry, pachymetry, and 
anterior chamber depth were assessed before eye drop 
administration, and then again at 0.5, 1, 2, 3, 4, and 5 h, 1 
week, and 1-month after administration in each eye and 
binocularly. The results revealed about a 2–3 lines of 
UNVA improvement from baseline in each eye and 
binocularly. There were no changes in UDVA measured in 
each eye or binocularly in the study population. The 
refractive measurements showed that there was a 
maximum myopic shift of 0.5 D, which decreased 
gradually and disappeared at 4 h [32]. 
The second paper, by Vargas et al., in 2019, reported a 
prospective, consecutive, interventional, non-
comparative clinical study on 117 patients with 
presbyopia, using 1 drop FOV tears (composed of 0.247% 
pilocarpine, 0.78% phenylephrine, 0.09% 
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polyethyleneglycol, 0.023% nepafenac, 0.034% 
pheniramine, and 0.003% naphazoline) in each eye, and 
assessed UNVA and UDVA 2 hours after instillation of eye 
drops. The patients were divided into 2 age groups: group 
1, aged 41‒50 years; and group 2, aged 51‒65 years. The 
UNVA and UDVA, objective scatter index (OSI), and pupil 
diameter under photopic and scotopic conditions before 
and after instillation were assessed. The results showed a 
change in UNVA from before to 2 h after the instillation, 
from 0.35 LogMAR to 0.16 LogMAR. In addition, 9 patients 
showed no UNVA improvement, and none of the patients 
showed a loss of lines. According to age, Group 1 gained 
more lines than Group 2. Evaluation of light scattering 
using the double-pass technique revealed no significant 
alteration in the OSI before and after eye drop instillation. 
However, a comparison between the groups showed a 
significant difference after the instillation of the eye 
drops.  A significant reduction in mean pupil size under 
photopic and scotopic conditions was detected at 2 h after 
treatment. Both groups showed a statistically significant 
change under both light conditions; however, the change 
in pupil size between photopic and scotopic conditions 
was not significant [43]. Table 2 summarizes studies which 
evaluated the efficacy and security of pharmacological 
treatment for presbyopia by restoring accommodation. 
Restoring the Crystalline Lens  
Presbyopia is thought to be due to loss of elasticity of the 
crystalline lens, through cumulative protein sulfhydryl 
group oxidation, protein cross-links form, and the lens 
fibers harden, causing accommodative amplitude 
reduction and blurred near vision. A quite different 
approach is proposed for presbyopia correction with eye 
drops. Novartis is investigating an ophthalmic solution 
EV06 (lipoic acid choline ester or LACE, 1.5%), an 
antioxidant that chemically cuts lens disulfide bonds, 
leads to greater cytosol displacement during 
accommodation, and subsequently amplifies dynamic 
crystalline lens refractive power [33]. According to 
Novartis, "This prodrug is designed to penetrate the 
cornea and then break down into lipoic acid and choline, 
2 naturally occurring substances” and lens fiber cells 
enzymes chemically reduce lipoic acid into active-form 
dihydrolipoic acid (DHLA), which reduces disulfide bonds 
between lens proteins, restoring lens microfluidics [58]. 
In a phase I‒II study, 50 subjects received 1 drop of EV06, 
and 25 subjects received a placebo twice a day for 90 days. 
The mean distance CNVA of the group that received EV06 
was improved. The drug was well tolerated with no 
treatment-related dropout and no significant changes in 
CDVA, pupil size, or intraocular pressure. On day 91, 82% 
of the treatment group had 20/40 CNVA or better, 
compared with 48% in the placebo group, with baseline 
values of 30% and 28%, respectively. Comparably, 60% of 
EV06 patients had 20/32 distance CNVA or better, 
compared with only 24% in placebo, while the baseline 
value was 8% in both groups. In addition, 36% of EV06 
patients had 20/20 and 20/25 distance CNVA compared 
with 16% in placebo, while the baseline value was 0% in 
both groups. Novartis expected EV06 to be a bilateral 
therapy. Moreover, this drug or a similar preparation 
might also benefit from slow or even avoid nuclear 
sclerosis, which is considered to arise from the same 
chemical process for presbyopia [59].  
 
DISCUSSION  
Collectively, our society is currently experiencing 
demographic shifts due to the aging of population in 
conjunction with the increase in life expectancy and the 
acquisition of new dynamic habits [60]. These habit 
changes in an older population are, in some way, 
supported by the use of new technologies such as 
cellphones, computers, and platforms and demand 
solutions to their physiological impairments. Nowadays, 
turning 40, 50, or 60 is not the same as in the past century 
because of the extended active life [61]. At the beginning 
of this century, 23% of the world population was affected 
by presbyopia; in 2015, 25%, which is 1.8 billion people 
and the prediction for 2030 is approximately 2.1 billion 
people [62]. The etymologically, presbyopia is an ocular 
affection in the elderly, which is in contrast to the vision 
of people of their selves in their forties and on. The 
classical solution of presbyopia is the prescription of 
glasses or contact lenses, while new surgical possibilities 
have emerged as PresbyLASYK, intracorneal inlays, and 
IOLs [9]. 
The newest improvement in the treatment of presbyopia 
is topical pharmacological treatment [26-28], which 
presents some remarkable advantages when compared to 
surgical methods in that it is non-invasive, reversible, and 
shows no significant adverse effects. Three 
pharmacological treatment approaches are in progress, 
with different states of development, practical 
implementation, practice, and results.  
The first is based on the induction of miosis with the 
enhancement of the depth-of-focus [44]. This pinhole 
effect is achieved by using a parasympathetic agonist 
(carbachol, pilocarpine, aceclidine) to produce miosis in 
combination with other substances (oxymetazoline, 
tropicamide, brimonidine). The instillation of eye drops is 
unilateral in the non-dominant eye. All the revised studies 
were performed on emmetropic patients who obtained 
20/20 of UDVA, also performed for short periods, which 
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did not allow the ability to know of the detriment of UDVA 
over time. This strategy prioritizes the near vision, 
sacrificing the distance vision [34-40, 47-51, 53-55]. 
The second approach is based on the restoration of 
accommodation, which is the ability to change the diopter 
power of the eye to focus by changing the distance of the 
object. Benozzi’s method uses eye drops with components 
of pilocarpine and diclofenac, while FOV uses a 
parasympathomimetic and NSAID and the addition of 
phenylephrine, pheniramine, naphazoline, and 
polyethyleneglycol [5, 32]. Both developments, Benozzi’s 
method, and FOV tears stimulate the ciliary body and 
allow physiological variations in the position and shape of 
the crystalline lens. The binocular treatment prevents 
deterioration of visual acuity and allows the image to 
merge with a clear focus at all distances  [5, 42, 43]. 
However, Benozzi’s method is the only treatment of all 
those reported in this review, which showed that it is a 
safe and effective option in a study of more than 900 
patients over 8 years [5].  
The third line of presbyopia treatment is based on the 
assumption that crystalline lens stiffness and loss of 
flexibility are the leading causes of presbyopia. The 
ophthalmic solution EV06 is an antioxidant, restoring lens 
microfluidics [59]. 
Pharmacological treatment of presbyopia is a very 
interesting option for emmetropic patients, especially for 
those who have just started presbyopia. On the 1 hand, it 
integrates with the joviality and vitality of a 45-year-old 
individual in our society; on the other hand, it allows total 
independence from glasses and their restrictions. It is 
expected that with the course and experience in the 
implementation of pharmacological treatment, patients 
with other refractive errors can be treated successfully.  
This review summarizes the results of three lines of 
investigation of pharmacological treatment for 
presbyopia, namely, producing miosis to take advantage 
of a pharmacologically induced pinhole effect, restoring 
accommodation, and attempting to rehabilitate the lost 
elasticity of the crystalline lens. However, despite its 
strengths, this study has the following limitations. 
Although the authors aimed to review the literature on 
pharmacological treatments for presbyopia, there is a 
possibility that we did not include all relevant treatment 
options, which may raise bias in the conclusions. Studies 
on pharmacological treatments for presbyopia have 
opened up a new field of research, and further 
investigations may pave the way for its use in routine 
clinical practice. Future perspectives on the 
pharmacological approach for treating presbyopia and its 
outcome measures will improve our understanding of this 
treatment method. In addition, clinical trials are essential 
to investigate safety and efficacy before generalizing 
these treatment modalities.  
CONCLUSIONS 
To date, there is no validated methodology for the 
objective measurement of accommodation that can 
evaluate whether drugs or formulations provide the best 
improvement in presbyopic patients. All of these 
formulations ameliorated presbyopia without relevant 
adverse effects. None of these treatments are prescribed 
globally, but patients with a restoring accommodation 
strategy can adhere locally where they are sold as master 
prescriptions. To date, Benozzi’s method has successfully 
treated 910 patients successfully. However, many of these 
developments are currently in registered clinical trials, so 
it is to be expected that in the coming years, we will have 
much news about these treatments and their 
implementation. None of the 3 discussed strategies of 
pharmacological treatment for presbyopia, prescribed 
globally, but patients of restoring accommodation 
strategy can adhere locally, where they are sold as master 
prescriptions. 
ETHICAL DECLARATIONS 
Ethical approval: This study was a review, and no ethical 
approval is required. 






1. Petrash JM. Aging and age-related diseases of the ocular lens 
and vitreous body. Invest Ophthalmol Vis Sci. 
2013;54(14):ORSF54-9. doi: 10.1167/iovs.13-12940 pmid: 
24335070 
2. Charman WN. Virtual Issue Editorial: Presbyopia - grappling with 
an age-old problem. Ophthalmic Physiol Opt. 2017;37(6):655-
60. doi: 10.1111/opo.12416 pmid: 29044672 
3. Mishra D, Bhushan P, Singh M, Makkar B, Sinha B, Bhaskar G. 
Prospective clinical study to find out epidemiology of presbyopia 
in a prepresbyopic population (age group 34–40 years). J Clin 
Ophthalmol Res. 2019;7(2):51.  
4. Croft MA, Glasser A, Kaufman PL. Accommodation and 
presbyopia. Int Ophthalmol Clin. 2001;41(2):33-46. doi: 
10.1097/00004397-200104000-00005 pmid: 11290920 
5. Benozzi G, Perez C, Leiro J, Facal S, Orman B. Presbyopia 
Treatment With Eye Drops: An Eight Year Retrospective Study. 




Med Hypothesis Discov Innov Optom. 2020; 1(2)  
76 OVERVIEW OF PHARMACOLOGICAL TREATMENTS FOR PRESBYOPIA 
6. Park H, Park IK, Shin JH, Chun YS. Objective Verification of 
Physiologic Changes during Accommodation under Binocular, 
Monocular, and Pinhole Conditions. J Korean Med Sci. 
2019;34(4):e32. doi: 10.3346/jkms.2019.34.e32 pmid: 
30686953 
7. Cardona G, Lopez S. Pupil diameter, working distance and 
illumination during habitual tasks. Implications for simultaneous 
vision contact lenses for presbyopia. J Optom. 2016;9(2):78-84. 
doi: 10.1016/j.optom.2015.06.005 pmid: 26481439 
8. Holden BA, Fricke TR, Ho SM, Wong R, Schlenther G, Cronje S, et 
al. Global vision impairment due to uncorrected presbyopia. 
Arch Ophthalmol. 2008;126(12):1731-9. doi: 
10.1001/archopht.126.12.1731 pmid: 19064856 
9. Wolffsohn JS, Davies LN. Presbyopia: Effectiveness of correction 
strategies. Prog Retin Eye Res. 2019;68:124-43. doi: 
10.1016/j.preteyeres.2018.09.004 pmid: 30244049 
10. Glasser A. Accommodation: mechanism and measurement. 
Ophthalmol Clin North Am. 2006;19(1):1-12, v. doi: 
10.1016/j.ohc.2005.09.004 pmid: 16500524 
11. Benozzi J, Benozzi G, Orman B. Presbyopia: a new potential 
pharmacological treatment. Med Hypothesis Discov Innov 
Ophthalmol. 2012;1(1):3-5. pmid: 24600609 
12. Rohen JW. Scanning electron microscopic studies of the zonular 
apparatus in human and monkey eyes. Invest Ophthalmol Vis 
Sci. 1979;18(2):133-44. pmid: 104933 
13. Charman WN. Developments in the correction of presbyopia I: 
spectacle and contact lenses. Ophthalmic Physiol Opt. 
2014;34(1):8-29. doi: 10.1111/opo.12091 pmid: 24205890 
14. Vargas-Fragoso V, Alio JL. Corneal compensation of presbyopia: 
PresbyLASIK: an updated review. Eye Vis (Lond). 2017;4:11. doi: 
10.1186/s40662-017-0075-9 pmid: 28413804 
15. Stival LR, Figueiredo MN, Santhiago MR. Presbyopic Excimer 
Laser Ablation: A Review. J Refract Surg. 2018;34(10):698-710. 
doi: 10.3928/1081597X-20180726-02 pmid: 30296331 
16. Ambrosio R, Jr. Post-LASIK Ectasia: Twenty Years of a 
Conundrum. Semin Ophthalmol. 2019;34(2):66-8. doi: 
10.1080/08820538.2019.1569075 pmid: 30664391 
17. Balgos M, Vargas V, Alio JL. Correction of presbyopia: An 
integrated update for the practical surgeon. Taiwan J 
Ophthalmol. 2018;8(3):121-40. doi: 10.4103/tjo.tjo_53_18 
pmid: 30294526 
18. Ong HS, Chan AS, Yau CW, Mehta JS. Corneal Inlays for 
Presbyopia Explanted Due to Corneal Haze. J Refract Surg. 
2018;34(5):357-60. doi: 10.3928/1081597X-20180308-01 pmid: 
29738595 
19. Mastropasqua L, Toto L, Nubile M, Falconio G, Ciancaglini M. 
Long-term complications of bilateral posterior chamber phakic 
intraocular lens implantation. J Cataract Refract Surg. 
2004;30(4):901-4. doi: 10.1016/j.jcrs.2003.08.012 pmid: 
15093658 
20. Greenstein S, Pineda R, 2nd. The Quest for Spectacle 
Independence: A Comparison of Multifocal Intraocular Lens 
Implants and Pseudophakic Monovision for Patients with 
Presbyopia. Semin Ophthalmol. 2017;32(1):111-5. doi: 
10.1080/08820538.2016.1228400 pmid: 27792408 
21. Schallhorn JM, Schallhorn SC, Teenan D, Hannan SJ, Pelouskova 
M, Venter JA. Incidence of Intraoperative and Early 
Postoperative Adverse Events in a Large Cohort of Consecutive 
Refractive Lens Exchange Procedures. Am J Ophthalmol. 
2019;208:406-14. doi: 10.1016/j.ajo.2019.08.025 pmid: 
31493400 
22. Labiris G, Toli A, Perente A, Ntonti P, Kozobolis VP. A systematic 
review of pseudophakic monovision for presbyopia correction. 
Int J Ophthalmol. 2017;10(6):992-1000. doi: 
10.18240/ijo.2017.06.24 pmid: 28730093 
23. Akella SS, Juthani VV. Extended depth of focus intraocular lenses 
for presbyopia. Curr Opin Ophthalmol. 2018;29(4):318-22. doi: 
10.1097/ICU.0000000000000490 pmid: 29697436 
24. Alio JL, Grzybowski A, Romaniuk D. Refractive lens exchange in 
modern practice: when and when not to do it? Eye Vis (Lond). 
2014;1:10. doi: 10.1186/s40662-014-0010-2 pmid: 26605356 
25. Westin O, Koskela T, Behndig A. Epidemiology and outcomes in 
refractive lens exchange surgery. Acta Ophthalmol. 
2015;93(1):41-5. doi: 10.1111/aos.12460 pmid: 24889146 
26. Karanfil FÇ, Turgut B. Update on presbyopia-correcting drops. 
Europ Ophthalm Rev. 2017;11(2):99–102 doi: 
https://doi.org/10.17925/EOR.2017.11.02.99  
27. Grzybowski A, Mimier M, Misiuk-Hojło M. Pharmacological 
treatment of presbyopia. OphthaTherapy Ther Ophthalmol. 
2017;4(4):237-40. doi: 10.24292/01.ot.291217.07  
28. Chou B. 'Presbyopia Eye Drops are in Sight'. Review of Cornea 
and Contact Lenses. 2018 [September 30, 2020]. Available from: 
https://www.reviewofcontactlenses.com/article/presbyopia-
eye-drops-are-in-sight. 
29. By Cheryl Guttman Krader; Reviewed by Claes Feinbaum (2015). 
'Simple solution for presbyopia'. Ophthalmoloy Times; 2015 
[September 15, 2020]. Available from: 
https://www.ophthalmologytimes.com/view/simple-solution-
presbyopia. 
30. Lipner M. 'A unique drop'. Eyeworld; 2014 [September 30, 2020]. 
Available from: https://www.eyeworld.org/article-a-unique-
drop. 
31. Wilcox CS, Heiser JF, Crowder AM, Wassom NJ, Katz BB, Dale JL. 
Comparison of the effects on pupil size and accommodation of 
three regimens of topical dapiprazole. Br J Ophthalmol. 
1995;79(6):544-8. doi: 10.1136/bjo.79.6.544 pmid: 7626570 
32. Renna A, Vejarano LF, De la Cruz E, Alio JL. Pharmacological 
Treatment of Presbyopia by Novel Binocularly Instilled Eye 
Drops: A Pilot Study. Ophthalmol Ther. 2016;5(1):63-73. doi: 
10.1007/s40123-016-0050-x pmid: 27168149 
33. Korenfeld MS, Evans DG, Rauchman SH, Sall KN, Stein JM, 
Robertson SM, et al. A Phase I/II clinical study evaluating the 
safety and efficacy of bilaterally dosed topical lipoic acid choline 
ester eye drops for the treatment of presbyopia. Invest 
Ophthalmol Visual Sci. 2017;58(8):331.  
34. Grzybowski A, Markeviciute A, Zemaitiene R. A Review of 
Pharmacological Presbyopia Treatment. Asia Pac J Ophthalmol 
(Phila). 2020 9(3):226-33. doi: 10.1097/APO.0000000000000297 
pmid: 32511122 
35. A Single-Center, Double-Masked Evaluation of the Efficacy and 
Safety of PRX-100 in the Treatment of Early to Moderate 
Presbyopia 2017. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03201562. 
36. Abdelkader A. Improved Presbyopic Vision With Miotics. Eye 
Contact Lens. 2015;41(5):323-7. doi: 
10.1097/ICL.0000000000000137 pmid: 25806674 
37. Abdelkader A, Kaufman HE. Clinical outcomes of combined 
versus separate carbachol and brimonidine drops in correcting 
presbyopia. Eye Vis (Lond). 2016;3:31. doi: 10.1186/s40662-
016-0065-3 pmid: 27981057 
38. Orasis Pharmaceuticals Ltd.Presbyopia. A Multi-Center, Double-
Masked Evaluation of the Efficacy and Safety of CSF-1 in the 
 
  
Med Hypothesis Discov Innov Optom. 2020; 1(2)  
77 OVERVIEW OF PHARMACOLOGICAL TREATMENTS FOR PRESBYOPIA 
Treatment of Presbyopia: ClinicalTrials.gov Identifier: 
NCT03885011; 2019. Available from: 
https://clinicaltrials.gov/ct2/show/NCT03885011  
39. Rodríguez Hernández J, Carrera Díaz H. 'Ophthalmic composition 
for correcting presbyopia 2013'. Google Patents.  2013 
[September 30, 2020]. Available from: 
https://patents.google.com/patent/WO2015092087A1/en. 
40. Moustafa FA, Sandoval LF, Feldman SR. Rosacea: new and 
emerging treatments. Drugs. 2014;74(13):1457-65. doi: 
10.1007/s40265-014-0281-x pmid: 25154627 
41. Facal S, Leiro J, Gualtieri A, Perez C, Benozzi G, Orman B. Ocular 
Surface Evaluation in Patients Treated with Pharmacological 
Treatment for Presbyopia. Int J Ophthalm Pathol. 2018;07(02). 
doi: 10.4172/2324-8599.1000218  
42. Benozzi G, Facal S, Leiro J, Perez C, Orman B. Stereopsis 
Restoration in Patients Under Pharmacological Treatment for 
Presbyopia. Oftalmología Clínica y Experimental. 2020;13(2):82-
9.  
43. Vargas V, Vejarano F, Alio JL. Near Vision Improvement with the 
Use of a New Topical Compound for Presbyopia Correction: A 
Prospective, Consecutive Interventional Non-Comparative 
Clinical Study. Ophthalmol Ther. 2019;8(1):31-9. doi: 
10.1007/s40123-018-0154-6 pmid: 30465236 
44. Sheri R. AAO 2019: Topical Treatments for Presbyopia on the 
Horizon 2019.: PracticeUpdate; 2019 [September 30, 2020]. 
Available from: https://www.practiceupdate.com/content/aao-
2019-topical-treatments-for-presbyopia-on-the-horizon/91112  
45. Naroo SA, Bilkhu PS. Clinical utility of the KAMRA corneal inlay. 
Clin Ophthalmol. 2016;10:913-9. doi: 10.2147/OPTH.S89132 
pmid: 27274194 
46. Schultz T, Dick HB. Small-Aperture Intraocular Lens Implantation 
in a Patient With an Irregular Cornea. J Refract Surg. 
2016;32(10):706-8. doi: 10.3928/1081597X-20160721-01 pmid: 
27722759 
47. Balal H, Gil-Cazorla R, Naroo S, Sharma A, Shah S. ‘Refractive 
surgery’s holy grail’. Eyedrops for presbyopia. . The 
Ophthalmologist. 2017:18-29. Available from: 
https://theophthalmologist.com/fileadmin/top/pdf/TOP_Issue
_0317NA.pdf. 
48. Kaufman S. ‘Addressing presbyopia pharmacologically’ 2012. 
Ophthamol Times. [September 30, 2020]. Available from: 
https://www.ophthalmologytimes.com/view/addressing-
presbyopia-pharmacologically. 
49. Abad J. Compositions and methods for treating presbyopia, mild 
hyperopia, and irregular astigmatism. Google Patents. 
WO2013041967A3. 2012 [September 30, 2020]. Available from: 
https://patents.google.com/patent/WO2013041967A3/en. 
50. Pavan-Langston D. Manual of ocular diagnosis and therapy: 
Lippincott Williams & Wilkins; 2008. 
51. Abdelkader A. A novel pharmacological treatment of 
pseudophakic presbyopia. Int J Ophthalmi Res. 2018;4(2):291-4. 
doi: 10.17554/j.issn.2409-5680.2018.04.85.  
52. Kaufman H, Donnenfeld E. 'Visus Therapeutics Launches and 
Announces Clinical Development Program for Novel Presbyopia 




53. Croft MA, Kaufman PL, Erickson-Lamy K, Polansky JR. 
Accommodation and ciliary muscle muscarinic receptors after 
echothiophate. Invest Ophthalmol Vis Sci. 1991;32(13):3288-97. 
pmid: 1748559 
54. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. 
Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000. doi: 
10.1161/ATVBAHA.110.207449 pmid: 21508345 
55. Allergan. Safety and Efficacy of AGN-199201 and AGN-190584 in 
Patients With Presbyopia 2014.: ClinicalTrials.gov Identifier: 
NCT02197806; 2014. Available from: 
https://clinicaltrials.gov/ct2/show/NCT02197806. 
56. Gross H, Blechinger F, Achtner B. Human Eye. In: Gross H, 
Blechinger F, Achtner B, editors. Handbook of Optical Systems, 
volume 4: Survey of Optical  instruments. Weinheim, Germany: 
Wiley-VCH Verlag GmbH Co. KGaA; 11 Apr 2008. 
57. Benozzi J, inventor. 'Ophthalmic compositions of 
parasympathetic stimulants and anti-inflammatories for use in 
the treatment of presbyopia'. Google Patents: EP 
1938839B1.2009 [September 30, 2020]. Available from: 
https://patents.google.com/patent/EP1938839B1/en#citedBy. 
58. Crawford KS, Garner WH, Burns W. Dioptin™: a novel 
pharmaceutical formulation for restoration of accommodation 
in presbyopes. Investigat Ophthalmol Visual Sci. 
2014;55(13):3765-.  
59. Larkin H. 'Presbyopia Eye Drops, Anti-crosslinking drug may 
restore natural accommodation 2017': EUROTIMES 2017 [May 
20, 2020]. Available from: 
https://www.eurotimes.org/presbyopia-eyedrops-lindstrom/. 
60. The United Nations. 'World Population Prospects 2019': the 
United Nations, Department of Economic and Social Affairs 
Population Dynamics.; 2019 [updated February 15, 2020]. 
Available from: https://population.un.org/wpp/DataQuery. 
61. Jackson M. 2019 Wilkins-Bernal-Medawar lectureLife begins at 
40: the demographic and cultural roots of the midlife crisis. . 
Notes Rec R Soc Lond. 2020 74(3):345-64. doi: 
10.1098/rsnr.2020.0008 pmid: 32831409 
62. Fricke T, Tahhan N, Resnikoff S, Papas E, Burnett A, Ho S, et al. 
Global Prevalence of Presbyopia and Vision Impairment from 
Uncorrected Presbyopia: Systematic Review, Meta-analysis, and 
Modelling. . Ophthalmology. 2018 125(10):1492-9. doi: 
10.1016/j.ophtha.2018.04.013 pmid: 29753495 
 
 
